Syncona supplied a third of the investment and retains a majority stake in Freeline, which is based on research at UCL.
Freeline, a UK-based gene therapy spinout from University College London (UCL) formed by commercialisation firm Syncona, today closed a $120m series C round featuring the latter investor.
Pharmaceutical firm Novo Holdings, investment adviser Eventide Asset Management and investment management firm Wellington Management Company co-led the round, which also featured Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund.
Syncona supplied $40m in a first tranche in December 2019 and retains a majority stake of 60%, down from 80%.
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
